

**IN THE CLAIMS**

This listing of claims replaces all prior versions, and listings, in this application.

1. (original) A drug, containing:

a metabolic product prepared by incubating a photosynthetic bacterium together with a lactic acid bacterium so as to cause the photosynthetic bacterium to produce a viscous material,

the photosynthetic bacterium being *Rhodopseudomonas capsulatas* FERMBP-7434 strain.

2. (original) The drug as set forth in Claim 1, wherein:

the metabolic product contains bacteriochlorophyll in a range of from 0.2 to 3.0 (% by weight).

3. (original) The drug as set forth in Claim 1, wherein:

the metabolic product contains bacteriochlorophyll in a range of from 0.6 to 1.9 (% by weight).

4. (original) The drug as set forth in Claim 1, wherein:

the metabolic product contains a carotinoid material in a range of 0.5 to 7.5 ( $\mu\text{mol/g}$ ).

5. (original) The drug as set forth in Claim 1, wherein:

the metabolic product contains a carotinoid material in a range of 2.4 to 4.0 ( $\mu\text{mol/g}$ ).

6. (original) The drug as set forth in Claim 1, wherein:

after subjected to acid hydrolysis, the metabolic product has glucose contents (weight %) ranging from 2.4 to 7.5, ribose contents (weight %) ranging from 0.3 to 1.1,

rhamnose contents (weight %) ranging from 1.0 to 3.3, fucose contents (weight %) ranging from 0.6 to 2.6.

7. (original) The drug as set forth in Claim 1, wherein:

after subjected to acid hydrolysis, the metabolic product has glucose contents (weight %) ranging from 3.5 to 6.5, ribose contents (weight %) ranging from 0.4 to 1.0, rhamnose contents (weight %) ranging from 1.2 to 3.0, fucose contents (weight %) ranging from 0.8 to 2.4.

8. (original) The drug as set forth in Claim 1, wherein:

after subjected to water-washing and subsequently to acid hydrolysis, the metabolic product has glucose contents (weight %) ranging from 0.8 to 3.3, ribose contents (weight %) ranging from 0.2 to 1.0, rhamnose contents (weight %) ranging from 0.4 to 2.0, fucose contents (weight %) of 0.6 or less.

9. (original) The drug as set forth in Claim 1, wherein:

after subjected to water-washing and subsequently to acid hydrolysis, the metabolic product has glucose contents (weight %) ranging from 1.0 to 3.0, ribose contents (weight %) ranging from 0.3 to 0.9, rhamnose contents (weight %) ranging from 0.5 to 1.6, fucose contents (weight %) of 0.5 or less.

10. (original) The drug as set forth in Claim 6, wherein:

after subjected to water-washing and subsequently to acid hydrolysis, the metabolic product has glucose contents (weight %) ranging from 0.8 to 3.3, ribose contents (weight %) ranging from 0.2 to 1.0, rhamnose contents (weight %) ranging from 0.4 to 2.0, fucose contents (weight %) of 0.6 or less.

11. (original) The drug as set forth in Claim 6, wherein:

after subjected to water-washing and subsequently to acid hydrolysis, the metabolic product has glucose contents (weight %) ranging from 1.0 to 3.0, ribose

contents (weight %) ranging from 0.3 to 0.9, rhamnose contents (weight %) ranging from 0.5 to 1.6, fucose contents (weight %) of 0.5 or less.

12. (original) The drug as set forth in Claim 7, wherein:

after subjected to water-washing and subsequently to acid hydrolysis, the metabolic product has glucose contents (weight %) ranging from 0.8 to 3.3, ribose contents (weight %) ranging from 0.2 to 1.0, rhamnose contents (weight %) ranging from 0.4 to 2.0, fucose contents (weight %) of 0.6 or less.

13. (original) The drug as set forth in Claim 7, wherein:

after subjected to water-washing and subsequently to acid hydrolysis, the metabolic product has glucose contents (weight %) ranging from 1.0 to 3.0, ribose contents (weight %) ranging from 0.3 to 0.9, rhamnose contents (weight %) ranging from 0.5 to 1.6, fucose contents (weight %) of 0.5 or less.

14. (original) The drug as set forth in Claim 1, wherein:

the lactic acid bacterium is *Lactobacillus* spp.

15. (currently amended) The [[Te]] drug as set forth in Claim 1, wherein:

the lactic acid bacterium is *Lactobacillus bulgaricus*.

16. (original) A method of manufacturing a drug, comprising the steps of:

incubating a photosynthetic bacterium together with a lactic acid bacterium so as to cause the photosynthetic bacterium to produce a viscous material in a liquid medium, the photosynthetic bacterium being *Rhodopseudomonas capsulatas* FERMBP-7434 strain; and

separating a metabolic product from the liquid medium.